Effects of imiglucerase on the growth and metabolism of Gaucher disease type i patients: A systematic review

Nutrition and Metabolism

Volumn 10, Issue 1, 2013, Pages

  Doneda, Divair ^a   Netto, Cristina B ^b   Moulin, Cileide C ^b   Schwartz, Ida Vanessa D ^a,b  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Gaucher Disease; Growth; Imiglucerase; Metabolism

Indexed keywords

ALGLUCERASE; IMIGLUCERASE;

BODY HEIGHT; BODY WEIGHT; CLINICAL TRIAL (TOPIC); DEVELOPMENT; DIABETES MELLITUS; ENZYME REPLACEMENT; GAUCHER DISEASE; GAUCHER DISEASE TYPE 1; GROWTH; HUMAN; HYPERMETABOLISM; INSULIN RESISTANCE; MALNUTRITION; MEDLINE; META ANALYSIS (TOPIC); METABOLISM; OBESITY; REVIEW; SYSTEMATIC REVIEW; SYSTEMATIC REVIEW (TOPIC);

EID: 84875882993     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-10-34     Document Type: Review

References (35)

1. Therapeutic Goals in the Treatment of Gaucher Disease. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, Giralt M, Grabowski GA, Mistry PK, Tylki-Szymanska A, Semin Hematol 2004 41 5 4 14 4 15468045 (Pubitemid 39311677)
2. Consensus Conference: A reappraisal of Gaucher disease-diagnosis and disease management algorithms. Mistry PK, Cappelini MD, Lukina E, Özsan H, Pascual SM, Rosembaum H, Solano MH, Spigelman Z, Villarrubia J, Watman NP, Massenkeil G, Am J Hematol 2011 86 1 110 115 10.1002/ajh.21888 21080341
3. Gaucher Disease: Molecular Biology and Genotype-Phenotype Correlations. Hruska KS, LaMarca ME, Sidransky E, Gaucher disease Boca Raton: CRC Taylor & Francis, Futerman AH, Zimran A, 2007 13 48
4. Pediatric non-neuronopathic Gaucher disease: presentation, diagnosis and assessment. Consensus statements. Grabowski GA, Andria G, Baldellou A, Campbell PE, Charrow J, Cohen IJ, Harris CM, Kaplan P, Mengel E, Pocovi M, Vellodi A, Eur J Pediatr 2004 163 58 66 10.1007/s00431-003-1362-0 14677061 (Pubitemid 38223386)
5. Gaucher disease: lessons from a decade of therapy. Grabowski GA, J Pediatr 2004 144 15 9 10.1016/j.jpeds.2004.01.050 15126979 (Pubitemid 38591270)
6. A practical approach to diagnosis and management of Gaucher's disease. Mistry PK, Abrahamov A, Bailliers Clin Haematol 1997 10 817 38 10.1016/S0950-3536(97)80042-X (Pubitemid 28022211)
7. Plasma glucosylceramide and ceramide in type 1 Gaucher disease patients: Correlations with disease severity and response to therapeutic intervention. Groener JEM, Poorthuis BJHM, Kuiper S, Hollak CEM, Aerts JMFG, Biochim Biophys Acta 2008 1781 1-2 72 8 18155675
8. Gaucher's Disease in Albanian Children: Casuistics and Treatment. Shehi B, Boçari G, Vyshka G, Xhepa R, Alushani D, Iran J Pediatr 2011 21 1 1 7 23056756
9. A cross-sectional, mono-centric pilot study of insulin resistance in enzyme replacement therapy patients with Gaucher Type I without overweight. Ucar SK, Coker M, Argin M, Akman S, Kara S, Simsek DG, Darcan S, Mol Genet Metab 2009 96 1 50 51 10.1016/j.ymgme.2008.10.001 19006678
10. Type 1 Gaucher disease: phenotypic expression and natural history in Japanese patients. Ida H, Rennert OM, Ito T, Maekawa K, Eto Y, Blood Cells Mol Dis 1998 24 1 73 81 10.1006/bcmd.1998.0172 9541479 (Pubitemid 28213193)
11. Enzyme replacement therapy for Gaucher's disease: the early Canadian experience. MacKenzie JJ, Amato D, Clarke JT, CMAJ 1998 159 10 1273 8 9861225 (Pubitemid 28554505)
12. The clinical an demographic characteristics of nonneuronopathic Gaucher disease in 887 children at diagnosis. Kaplan P, Andersson HC, Kacena KA, Yee JD, Arc Pediatr Adolesc Med 2006 160 603 608 10.1001/archpedi.160.6.603 (Pubitemid 43854401)
13. Phenotype and mutational spectrum in Tunisian pediatric Gaucher disease. Ben Turkia H, Riaahi I, Azzouz H, Ladab S, Cherif W, Ben Chehida A, Abdelmoula MS, Caillaud C, Chemli J, Abdelhak S, Tebib N, Ben Dridi MF, Tunis Med 2010 88 3 158 62 20415187
14. Delayed Growth and Puberty in Patients with Gaucher Disease Type 1: Natural History and Effect of Splenectomy and/or Enzyme Replacement Therapy. Kauli R, Zaizov R, Lazar L, Pertzelan A, Laron Z, Galatzer A, Phillip M, Yaniv Y, Cohen IJ, Isr Med Assoc J 2000 2 2 158 163 10804944 (Pubitemid 30662162)
15. Outcome of enzyme replacement therapy in patients with Gaucher disease type I. The Romanian experience. Grigorescu Sido P, Drugan C, Cret V, Al-Kzouz C, Denes C, Coldea C, Zimmermann A, J Inherit Metab Dis 2007 30 5 783 9 10.1007/s10545-007-0621-z 17703370 (Pubitemid 47559891)
16. Adult-type Gaucher disease in children: genetics, clinical features and enzyme replacement therapy. Zevin S, Abrahamov A, Hadas-Halpern I, Kannai R, Levy-Lahad E, Horowitz M, Zimran A, Q J Med 1993 86 9 565 73 8255971 (Pubitemid 23272610)
17. Enzyme replacement treatment in type 1 and type 3 Gaucher's disease. Bembi B, Zanatta M, Carrozzi M, Baralle F, Gornati R, Berra B, Agosti E, Lancet 1994 344 8938 1679 82 10.1016/S0140-6736(94)90462-6 7996964 (Pubitemid 24371101)
18. Acceleration of retarded growth in children with Gaucher Disease after treatment with alglucerase. Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, Gribble TJ, Wappner RS, Wisch JS, Weinreb NJ, J Pediatr 1996 129 1 149 153 10.1016/S0022-3476(96)70203-2 8757576 (Pubitemid 26277260)
19. Aspectos clínicos e nutricionais da doença de Gaucher: estudo prospectivo de 13 crianças em um único centro. Oliveira MCLA, Oliveira BM, Queirós E, Viana MB, J Pediatr (Rio J) 2002 78 6 517 522 10.2223/JPED.909 (Pubitemid 36168765)
20. Clinical Consequences of Interrupting Enzyme Replacement Therapy in Children with Type Gaucher Disease. Drelichman G, Ponce E, Basack N, Freigeiro D, Aversa L, Graciela E, Kohan R, J Pediatr 2007 151 197 201 10.1016/j.jpeds.2007.02.057 17643778 (Pubitemid 47069396)
21. Avaliação de dois anos de tratamento da doença de Gaucher tipo I com terapia de reposição enzimática em pacientes do estado de São Paulo, Brasil. Sobreira EAP, Bruniera P, Rev Bras Hematol Hemoter 2008 30 3 193 201
22. Eight-year clinical outcomes of long-term enzyme replacement therapy for 884 children with Gaucher disease type 1. Andersson H, Kaplan P, Kacena K, Yee J, Pediatrics 2008 122 6 1182 90 10.1542/peds.2007-2144 19047232
23. Increased Basal Glucose Production in Type 1 Gaucher's Disease. Corssmit EP, Hollak CE, Endert E, van Oers MH, Sauerwein HP, Romijn JA, J Clin Endocrinol Metab 1995 80 9 2653 2657 10.1210/jc.80.9.2653 7673407
24. Differential Effects of Enzyme Supplementation Therapy on Manifestations of Type 1 Gaucher Disease. Hollak CE, Corssmit EP, Aerts JM, Endert E, Sauerwein HP, Romijn JA, van Oers MH, Am J Med 1997 103 3 185 191 10.1016/S0002-9343(97) 00134-4 9316550 (Pubitemid 27413400)
25. Very low serum adiponectin levels in patients with type 1 Gaucher disease without overt hyperglycemia. Langeveld M, Scheij S, Dubbelhuis P, Hollk CE, Sauerwein HP, Simons P, Aerts JM, Metabolism 2007 56 3 314 319 10.1016/j.metabol.2006.10.014 17292718 (Pubitemid 46209222)
26. Type I Gaucher disease, a glycosphingolipid storage disorder, is associated with insulin resistance. Langeveld M, Ghauharali KJ, Sauerwein HP, Ackermans MT, Groener JE, Hollak CE, Aerts JM, Serlie MJ, J Clin Endocrinol Metab 2008 93 3 845 851 18089699 (Pubitemid 351398562)
27. Prominent increase in plasma ganglioside GM3 is associated with clinical manifestations of type I Gaucher disease. Langeveld M, Poppema A, Kuiper S, Hollak CE, Aerts JM, Groener JE, Ghauharali-Van Der Vlugt K, Clin Chim Acta 2008 389 1-2 109 13 18164265
28. Imiglucerase low-dose therapy for paediatric Gaucher disease-a long-term cohort study. Heitner R, Arndt S, Levin JB, S Afr Med J 2004 94 8 647 51 15352589 (Pubitemid 39173236)
29. Insulin-like growth factors in childhood-onset Gaucher disease. Rite S, Baldellou A, Giraldo P, Labarta JI, Giralt M, Rubio-Felix D, Guallar A, Perez-Calvo JI, Mayayo E, Ferrandez A, Pocovi M, Pediatr Res 2002 52 1 109 12 10.1203/00006450-200207000-00020 12084856 (Pubitemid 34665959)
30. Type I Gaucher disease in children with and without enzyme therapy. Dweck A, Abrahamov A, Hadas-Halpern I, Bdolach-Avram T, Zimran A, Elstein D, Pediatr Hematol Oncol 2002 19 6 389 97 10.1080/08880010290097143 12186361 (Pubitemid 34919510)
31. Resting Energy Expenditure in Gaucher's Disease Type 1: Effect of Gaucher's Cell Burden on Energy Requirements. Barton DJ, Ludman MD, Benkov K, Grabowski GA, LeLeiko NS, Metabolism 1989 38 12 1238 1243 10.1016/0026-0495(89) 90165-0 2593834 (Pubitemid 20015501)
32. Gaucher disease type I: Assessment of basal metabolic rate in patients from southern Brazil. Doneda D, Lopes AL, Oliveira AR, Netto CB, Moulin CC, Schwartz IV, Blood Cells Mol Dis 2011 46 1 42 46 10.1016/j.bcmd.2010.10.008 21075022
33. Overweight, insulin resistance and type II diabetes in type I Gaucher disease patients in relation to enzyme replacement therapy. Langeveld M, de Fost M, Aerts JM, Sauerwein HP, Hollak CE, Blood Cells Mol Dis 2008 40 3 428 32 10.1016/j.bcmd.2007.09.002 17950007 (Pubitemid 351512343)
34. Gaucher Disease Recommendations on Diagnosis, Evaluation, and Monitoring. Charrow J, Esplin JA, Gribble TJ, Kaplan P, Kolodny EH, Pastores GM, Scott CR, Wappner RS, Weinreb NJ, Wisch JS, Arch Intern Med 1998 158 16 1754 1760 10.1001/archinte.158.16.1754 9738604 (Pubitemid 28421418)
35. Hypermetabolism in Gaucher disease type I is not associated with altered thyroid hormone levels. Langeveld M, Endert E, Wiersinga WM, Aerts JM, Hollak CE, J Inherit Metab Dis 2007 30 6 985 10.1007/s10545-007-0715-7 17912612